Clean product-level table
Company, ticker, product, indication, therapeutic area, reported category, currency, and quarter columns in a format that works for filters, pivots, and charts.
Quarterly pharmaceutical product sales database
Drug sales data, cleaned for investor analysis.
A structured Excel workbook for tracking product-level pharma revenue across major companies, therapeutic areas, launches, and quarter-by-quarter momentum.
Current edition includes Excel data plus an interactive HTML preview. Replace the buy link with the live Gumroad product URL when ready.
27major pharma companies in the current build
550+tracked product lines and reported franchises
8quarters from 2024 Q2 through 2026 Q1
XLSXExcel workbook with USD and local-currency views
What you get
A practical spreadsheet for people who actually open spreadsheets.
The product is the workbook. The chart is there to make the data easier to feel, share, and inspect before you start filtering.
USD view plus raw context
Directional USD conversions make cross-company ranking easier, while local-currency fields preserve company-reported context where it matters.
Interactive preview included
A companion HTML view highlights revenue rank changes and growth races, useful for quickly spotting commercial momentum before deeper analysis.
Visual preview
See launches and franchises move across quarters.
Use the preview as a hook, then use the spreadsheet for the real work: sorting, filtering, comparing, and building your own views.
Rank by sales
Compare the largest product franchises across companies without manually stitching together earnings appendices.
Growth race
Surface product launches and fast-growing franchises by absolute revenue added, not just percent growth from a tiny base.
Sample download
Inspect the structure before buying.
The sample is intentionally small: six non-GLP rows, three quarters, and limited fields. It shows the schema without replacing the paid workbook.
| Company | Product | Area | 2026 Q1 |
|---|---|---|---|
| Merck & Co. | Keytruda | Oncology | 8648 |
| Johnson & Johnson | DARZALEX | Oncology | 3324 |
| AbbVie | Skyrizi | Immunology | 3423 |
| Bristol Myers Squibb | Eliquis | Hematology | 3365 |
Built for screening
Useful without pretending to be a terminal.
This is a compact data product for investment research, not a giant BI platform. The value is cleanup, normalization, and faster comparison.
Good for
Spotting launch ramps, comparing leading drug franchises, screening therapeutic areas, and saving time otherwise spent pulling numbers from filings, PDFs, and investor appendices.
Important limits
Company-reported product sales can vary by disclosure style. USD conversions are directional. This is research data, not investment advice or audited financial reporting.
FAQ
Small answers before you buy.
What format do I get?
An Excel workbook plus an interactive HTML preview. The workbook is the core deliverable.
How often is it updated?
The goal is to update after major quarterly reporting cycles, with priority on the companies and products investors care about most.
How accurate is the data?
It is built from company-reported product sales and cleaned for analysis. Because companies report differently, some judgment and normalization are involved.
Is this investment advice?
No. It is a structured research dataset for screening and analysis.
Why not just use filings?
You can. The point is saving the collection and cleanup time across earnings workbooks, presentations, PDFs, SEC filings, currencies, and reporting conventions.
Can I request a company or correction?
Yes. Email hello [at] drugsalesdb [dot] com for requests, corrections, or data questions.
Start with the spreadsheet. Let the charts point you where to look.
Track top drug franchises, launches, and product-sales momentum across major pharma companies in one clean workbook.